menu
    • menu

    Company profile for Hillhurst Biopharmaceuticals

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a private biopharmaceutical company based in Southern California, founded in 2012 to realize the medical potential of over fifty years of research into the therapeutic use of low dose carbon monoxide as a therapeutic agent.. Our technology was co-invented by Edward Gomperts, a hematologist at Children’s Hospital Los Angeles with extensive biopharmaceutical industry experience. A substantial pre-clinical literature h...
    We are a private biopharmaceutical company based in Southern California, founded in 2012 to realize the medical potential of over fifty years of research into the therapeutic use of low dose carbon monoxide as a therapeutic agent.. Our technology was co-invented by Edward Gomperts, a hematologist at Children’s Hospital Los Angeles with extensive biopharmaceutical industry experience. A substantial pre-clinical literature has elucidated the mechanism and efficacy of carbon monoxide and its target cytoprotective pathway, heme oxygenase, to reduce the inflammation and cell death associated with sickle cell disease and Parkinson’s disease

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Hillhurst BiopharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2029 Verdugo Blvd., #125 Montrose, CA 91020
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://hillhurstbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hillhurst Starts Ph2a Trial of HBI-002 for Sickle Cell Disease
    Hillhurst Starts Ph2a Trial of HBI-002 for Sickle Cell Disease

    23 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hillhurst-biopharmaceuticals-doses-first-subject-in-phase-2a-clinical-trial-of-hbi-002-a-novel-therapy-for-sickle-cell-disease-302511133.html

    PR NEWSWIRE
    23 Jul 2025
    Share Share
    Hillhurst Biopharma Completes Seed Financing To Advance Clinical Development
    Hillhurst Biopharma Completes Seed Financing To Advance Clinical Development

    20 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hillhurst-biopharma-completes-seed-financing-to-advance-clinical-development-302019730.html

    PR NEWSWIRE
    20 Dec 2023
    Share Share
    Hillhurst Biopharmaceuticals Receives $3 Million In Nih Sbir Funding
    Hillhurst Biopharmaceuticals Receives $3 Million In Nih Sbir Funding

    20 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hillhurst-biopharmaceuticals-receives-3-million-in-nih-sbir-funding-for-phase-2a-clinical-study-in-sickle-cell-disease-301932754.html

    PR NEWSWIRE
    20 Sep 2023
    Share Share
    HILLHURST ANNOUNCES COMPLETION OF LAST PATIENT IN PHASE 1 TRIAL OF HBI-002
    HILLHURST ANNOUNCES COMPLETION OF LAST PATIENT IN PHASE 1 TRIAL OF HBI-002

    23 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hillhurst-biopharmaceuticals-announces-completion-of-last-patient-last-visit-in-phase-1-clinical-trial-of-hbi-002-301831438.html

    PR NEWSWIRE
    23 May 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search